IJFANS INTERNATIONAL JOURNAL OF FOOD AND NUTRITIONAL SCIENCES
ISSN PRINT 2319 1775 Online 2320 7876

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 11, Nov 2022

The Common Cold: A Review of the Literature

Dr Abhishek Kumar, Assistant Professor,
Department of T.B. & Chest, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India
Email Id- kumar010290@gmail.com

ABSTRACT: ***The most common illness in humans is respiratory viral infections, commonly known as the common cold. Despite their innocuous appearance, they are a leading source of illness and death throughout the globe. Several viruses have been linked to this kind of disease, including The most common is rhinovirus. Symptom generation is the result of a combination of viral cytotoxicity and inflammatory system activation. As a result, antiviral therapy alone may not be enough to avoid severe complications. The most effective use of such drugs necessitates an early start. As a result, developing reliable and quick diagnosis methods for respiratory viruses is critical. Prior to any dependable and efficient. Although therapy is accessible, symptomatic treatments may be the sole option for treatment. All intellectual property rights are retained.***

KEYWORDS: ***Rhinovirus; Influenza; Respiratory syncytial virus; Common cold***

1. INTRODUCTION

The common cold is the most common infectious disease that affects humans. The majority of people think of colds as rhinitis with varying degrees of pharyngitis, but the most common symptoms are nasal stuffiness and discharge, sneezing, sore throat, cough, and hoarse voice. Chills are common in patients, but a substantial increase in temperature is uncommon. Colds are generally self-limiting in previously healthy people, although there are known consequences including subsequent bacterial infections, asthma exacerbations, chronic obstructive pulmonary disease, and cystic fibrosis. Despite the fact that most instances of the disease are benign, it is nevertheless a substantial financial burden on society[1]. It causes an increase in clinician visits, greater absenteeism from school and work, and, as a result, a loss of wages.

Although the name "common cold" implies that the disease is caused by a single virus, it is really caused by any of a huge number of antigenetically different viruses. Direct hand contact with infected skin and ambient surfaces spreads the virus (RSV). The virus is then self-inoculated into the nasal mucosa or conjunctiva. Airborne transmission of rhinovirus is also feasible, although it is dependent on the length of time spent in contact with infected people[2]. The parainfluenza virus (PIV) is transmitted via big particle aerosol dispersal or direct person-to-person contact. The high incidence of infection in children, along with the high rate of reinfection, indicates that they are transmitted from person to person[3]. Two-thirds of participants experienced flu-like symptoms after a low-titre PIV intranasal challenge, indicating that the infectious dosage of PIV is minimal. Infected respiratory secretions transmit RSV. Large particle aerosol or direct contact with self-inoculation seem to be the most common modes of transmission. Close contact with an infected person or contamination of the hands followed by introduction into the conjunctiva are both required for spread. Small-particle aerosols are the most common way for influenza to spread[4]. For each virus, the relative effectiveness of the different transmission pathways under natural circumstances is unclear. Seasonal variations in the prevalence of several respiratory viruses are common. Although it is difficult to anticipate the precise seasonal fluctuation of any virus in the population, there are

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 11, Nov 2022

certain generalizations that may assist plan infection control measures. RSV and influenza outbreaks, for example, are more common during the winter months[5].

In the northern hemisphere, the peak season is from January through March. Infections with parainfluenza virus type 3 (PIV3) peak in the spring, whereas infections with parainfluenza virus type 1 (PIV1) and parainfluenza virus type 2 (PIV2) peak in the fall and early winter. Throughout the year, rhinovirus and adenovirus may be isolated[6].

More than 100 serotypes of rhinovirus have been discovered since the virus's discovery in 1956, and their relative frequency seems to fluctuate across geographical regions and over time. Infections of the upper respiratory tract caused by these viruses are the most frequent in people of all ages. Schoolchildren are the reservoir for rhinovirus, which they spread among their classmates and infect other family members at home[7].

The parainfluenza virus is the most frequent cause of croup (acute laryngotracheobronchitis) in young infants, accounting for 5% of all cold causes. On the basis of antigenic differences, human parainfluenza viruses are divided into four kinds. Direct contact with infected respiratory secretions or large-particle aerosols is how they spread from person to person. The incubation phase lasts between 3 and 6 days. Lower respiratory infections are common among bone marrow transplant patients, children with bronchopulmonary dysplasia, preterm, congenital heart disease, or asthma, and they need extra oxygen support. Secondary bacterial infections are believed to occur in one-third of children who have a lower respiratory illness caused by parainfluenza[8].

Coronavirus is responsible for 7–26% of all adult upper respiratory tract infections. Short-lived immunity is a key characteristic of coronavirus infection, which leads to a high incidence of reinfection. Aerosol inhalation is most likely the mechanism of transmission of coronavirus. However, since it does not develop well in cell culture, its virology is not completely understood. SARS-associated coronavirus (SARSCoV), a new coronavirus, has recently been suggested as the origin of the severe acute respiratory syndrome (SARS) epidemic. The virus causes unusual pneumonia symptoms that are clinically indistinguishable from comparable diseases.[9] The situation is so serious that a 15% death rate has been recorded. There is yet to be found a therapy that is consistently effective. Droplet spread is used for transmission, which necessitates intimate contact. Infection control measures are strictly enforced in health-care facilities[10].

The pandemic was brought to an end by widespread isolation measures in afflicted areas and worldwide monitoring with travel restrictions. As of July 11, 2003, 8437 individuals have been afflicted in 32 countries, with 813 fatalities recorded.

Influenza virus infection is responsible for 5–15% of common colds. Small-particle aerosol transmission has been linked to many epidemics, and it may maintain its infectivity for extended periods of time after being aerosolized in low-humidity circumstances. Influenza is distinguished from other respiratory viruses by two characteristics. First, influenza viruses may generate new strains against which the majority of the population has no protection, resulting in global epidemics. Antigenic shift or drift is a distinctive characteristic of antigenic variation. Second, a recent epidemic of the deadly H5N1 influenza subtype in humans raised the possibility of direct transmission between people and infected birds without the need of an intermediary host. This strain of avian influenza produced significant mortality, killing 70–

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 11, Nov 2022

100% of chickens and 6 people. Apart from the surface genes, there was a significant percentage of amino acid changes in all gene products of the H5N1 influenza virus, which supports antigenic drift.

RSV (respiratory syncytial virus) is a very effective human disease, infecting 95 percent of all infants by the age of two. It spreads from person to person or via contact with infected surfaces in the environment.

However, since the virus is inactivated in aerosols, transmission through aerosolized droplets is improbable. Incubation may take anything from a few days to a week. RSV protection is only partial, and reinfection is the norm (Table 1).

The tissue culture technique was used to identify the first significant respiratory viruses, adenoviruses. There are 47 distinct serotypes, each of which is linked with a particular disease.

Table 1: Characteristics of different types of Respiratory Viruses

	Mode of transmission	Incubation period	Seasonality
Rhinovirus	airborne/by large particle aerosol	2–7 days	early autumn/late spring
Coronavirus	possibly airborne	2–4 days	winter/early spring
Influenza	airborne/by small-particle aerosol	1–4 days	winter/spring
RSV	large-particle aerosol/direct contact with self-inoculation	4–5 days	autumn to spring
PIV	large-particle aerosol/direct contact with self-inoculation	3–10 days	PIV1 and 2—autumn PIV3—throughout the year
Adenovirus	airborne/direct contact with self-inoculation	4–14 days	late autumn/late spring

Infections in humans. The incubation phase usually lasts 4–7 days, although it may last up to 2 weeks. It is believed to be responsible for approximately 10% of all common colds in children, as well as a significant rate of neonatal death.

Human meta-pneumo virus (HMPV), a novel pneumo virus, was recently discovered in the Netherlands. Taxonomically, it is closely linked to RSV. During the winter season, this virus may be responsible for approximately 10% of unexplained respiratory illnesses in children. Seroprevalence studies indicate that the virus has been circulating in humans for at least 50 years, that 25% of children develop antibodies to the virus by the age of one year, and that by the age of five, almost everyone is seropositive. HMPV was found in two clusters in the amplified sequences. HMPV may cause a variety of symptoms, ranging from minor upper respiratory symptoms to serious infections requiring hospitalization. This clinical picture seems quite similar to that of other respiratory viruses. HMPV infection with other respiratory viruses is rare, and its function in human respiratory infections is yet unknown. This novel virus will undoubtedly require long-term monitoring.

Pathogenesis

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 11, Nov 2022

Respiratory viruses vary from bacteria in that they are able to bypass the mucociliary escalator and the host's nonimmunologic defenses. Furthermore, the pathophysiology of respiratory viruses is still a mystery. This may be because various viruses invade in different ways and infect different locations, causing varying degrees of damage to the respiratory tract lining.

Rhinovirus, the most prevalent cold virus, which accounts for 80% of all upper respiratory infections in the fall, usually infects the upper respiratory tract with little nasal epithelial damage, while influenza mostly affects the lower airways and causes significant damage. Because rhinovirus is so prevalent, the majority of research on common colds are based on it. The virus attaches to host cell intercellular adhesion molecule-1 (ICAM1) receptors at the back of the throat after initial deposits in the eyes and nose. There is no substantial increase in the number of inflammatory cells once within the nasal epithelial cell, although increases in neutrophils have been observed in nasal mucosa and secretions. This may be due to the production of inflammatory cytokines such kinins, leukotrienes, histamines, interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor, and RANTES (controlled by activation normal T-cell produced and released), which are responsible for some of the symptoms. Kinins, interleukin-1, interleukin-6, and interleukin-8 levels in nasal secretions have also been linked to symptom intensity and duration.

2. DISCUSSION

The Common Cold Unit at Harvard Hospital in Salisbury and the Department of Internal Medicine at the University of Virginia Health Sciences Center in Charlottesville, Virginia, performed many of the research examined here. In the last ten years, there have been a number of outstanding evaluations on the topic.because the number of well-designed published studies was high, research designs were varied, and outcome analysis was inconsistent, I opted not to conduct a formal meta-analysis when presenting this data. Many research relied on subjective symptom reporting, making it difficult to evaluate the findings. Both the viral challenge paradigm and the natural cold model have benefits and drawbacks. Rhinovirus was employed in almost all experimentally generated investigations, which is epidemiologically sound but clearly gives an incomplete response.

Symptomatic measures, such as anticholinergics; pharmacological blockers, such as nonsteroidal anti-inflammatory medications; and antivirals, such as interferon alfa-2b, are the three types of treatments for the common cold. The fact that viral replication in the upper respiratory tract peaks on the day symptoms begin is a significant impediment to finding an effective therapy for the common cold. As a result, several of these trials focused on starting therapy within 24 hours after the beginning of symptoms.

The behavior of physicians has been linked to a rhinovirus particle. A family study was conducted recently. According to the 35-practice teaching clinic, 26% of patients treated for upper respiratory tract infections were given unneeded medications. 46 Doctors may erroneously think that patient happiness is dependent on getting medications, when it would be more suitable to spend time educating patients about medications and when it is essential to visit a doctor. Because two-thirds of households have several over-the-counter cold medications, the risk of toxicity, especially in children, is high; cough and cold preparations accounted for 6.2 percent of all poisonings in children in the United States in 1996.

There are a few limitations to this study that should be acknowledged. To begin with, any database search may overlook some items due to variations in key phrases or headers. Second,

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 11, Nov 2022

some manufacturers may promote the usage of their products using unreported data from corporate studies. Third, investigations of naturally occurring common cold in various areas of the globe may be assessing distinct viruses, while studies of artificially generated cold may only evaluate a limited number of viral culprits.

3. CONCLUSION

The discovery of human meta-pneumo virus and the development of molecular methods for viral detection are both recent developments. In the study of the common cold, this is an exciting moment. More study into the host's inflammatory response, as well as the utilization of combination treatments, may lead to a long-term therapeutic option for this severe illness. In the meanwhile, as doctors, we must focus on patient education about vaccination and avoid prescribing unneeded antibiotics. In conclusion, treating symptoms is still the best choice for treating a common cold. Mast cell stabilisers, interferon alfa2b, and zinc lozenges are among the other potential agents. Although a medication combination may be the most obvious solution, cost and compliance remain major practical issues. Meanwhile, it is our duty to prevent unneeded and possibly dangerous medicines, as well as to inform our patients about when to seek medical counsel and the efficacy (or lack thereof) of various therapies.

REFERENCES:

[1] S. Sasazuki, "Vitamin C and the common cold," *Japanese J. Chest Dis.*, 2016.

[2] A. A. Prather, D. Janicki-Deverts, M. H. Hall, and S. Cohen, "Behaviorally assessed sleep and susceptibility to the common cold," *Sleep*, 2015.

[3] D. Simancas-Racines, J. V. A. Franco, C. V. Guerra, M. L. Felix, R. Hidalgo, and M. J. Martinez-Zapata, "Vaccines for the common cold," *Cochrane Database of Systematic Reviews*. 2017.

[4] M. S. Al-Haddad, Q. M. Abdallah, A. H. Alhamyani, A. J. Althomali, and S. M. Alshakhshir, "General public knowledge and practices about the common cold," *J. Taibah Univ. Med. Sci.*, 2016.

[5] S. Sasazuki, S. Sasaki, Y. Tsubono, S. Okubo, M. Hayashi, and S. Tsugane, "Effect of vitamin C on common cold: Randomized controlled trial," *Eur. J. Clin. Nutr.*, 2006.

[6] S. Maggini, S. Beveridge, and M. Suter, "A combination of high-dose vitamin C plus zinc for the common cold," *J. Int. Med. Res.*, 2012.

[7] E. Lissiman, A. L. Bhasale, and M. Cohen, "Garlic for the common cold," *Cochrane Database of Systematic Reviews*. 2014.

[8] D. Wat, "The common cold: A review of the literature," *European Journal of Internal Medicine*. 2004.

[9] E. J. Kang, S. Y. Kim, I. H. Hwang, and Y. J. Ji, "The effect of probiotics on prevention of common cold: A meta-analysis of randomized controlled trial studies," *Korean J. Fam. Med.*, 2013.

[10] H. Hemilä, E. J. Petrus, J. T. Fitzgerald, and A. Prasad, "Zinc acetate lozenges for treating the common cold: an individual patient data meta-analysis," *Br. J. Clin. Pharmacol.*, 2016.